COLLEGIUM PHARMACEUTICAL, INC (COLL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q1 '17: 2.2M Q2 '17: 3.6M Q3 '17: 11.9M Q4 '17: 10.8M Q1 '18: 63.7M Q2 '18: 73.1M Q3 '18: 70.2M Q4 '18: 73.4M Q1 '19: 74.5M Q2 '19: 75M Q3 '19: 72.9M Q4 '19: 74.2M Q1 '20: 76.5M Q2 '20: 78.1M Q3 '20: 79.2M Q4 '20: 76.3M Q1 '21: 87.7M Q2 '21: 82.9M Q3 '21: 78.8M Q4 '21: 27.4M Q1 '22: 83.8M Q2 '22: 123.5M Q3 '22: 127M Q4 '22: 129.6M Q1 '23: 144.8M Q2 '23: 135.5M Q3 '23: 136.7M Q4 '23: 149.7M Q1 '24: 144.9M Q2 '24: 145.3M Q3 '24: 159.3M Q4 '24: 181.9M Q1 '25: 177.8M Q2 '25: 188M Q3 '25: 209.4M Q4 '25: 205.4M Q1 '26: 193.5M Q2 '26: 199.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-50M 0 50M 100M 150M Q1 '19: 25.4M Q2 '19: 26.4M Q3 '19: 26.2M Q4 '19: 25.1M Q1 '20: 39M Q2 '20: 48.4M Q3 '20: 48.2M Q4 '20: 44.3M Q1 '21: 55.6M Q2 '21: 50.2M Q3 '21: 46.1M Q4 '21: -1.3M Q1 '22: 48.5M Q2 '22: 52.4M Q3 '22: 58.8M Q4 '22: 49.8M Q1 '23: 77.4M Q2 '23: 73.8M Q3 '23: 80.3M Q4 '23: 94.6M Q1 '24: 91.5M Q2 '24: 90.8M Q3 '24: 96.8M Q4 '24: 98.3M Q1 '25: 97.3M Q2 '25: 108.4M Q3 '25: 129.2M Q4 '25: 128.4M Q1 '26: 117.2M Q2 '26: 110.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income Quarterly

-50M -25M 0 25M 50M 75M Q1 '14: -3.7M Q2 '14: -4.1M Q3 '14: -6.5M Q4 '14: -3.3M Q1 '15: -3.6M Q2 '15: -4.6M Q3 '15: -9.3M Q4 '15: -9.4M Q1 '16: -15.6M Q2 '16: -24.5M Q3 '16: -26.4M Q4 '16: -27.6M Q1 '17: -23.2M Q2 '17: -21.3M Q3 '17: -13.4M Q4 '17: -17.6M Q1 '18: -13.2M Q2 '18: -7.3M Q3 '18: -11.2M Q4 '18: 11M Q1 '19: -10M Q2 '19: -5M Q3 '19: -6.4M Q4 '19: -2.4M Q1 '20: 5.1M Q2 '20: 16.5M Q3 '20: 19.6M Q4 '20: 15M Q1 '21: 21.2M Q2 '21: 16.4M Q3 '21: 14.1M Q4 '21: -34.1M Q1 '22: -10M Q2 '22: 11.1M Q3 '22: 20.5M Q4 '22: 11.8M Q1 '23: 24.6M Q2 '23: 35.6M Q3 '23: 45M Q4 '23: 61.7M Q1 '24: 49.5M Q2 '24: 47.5M Q3 '24: 34.8M Q4 '24: 38.1M Q1 '25: 21.7M Q2 '25: 35.1M Q3 '25: 62.1M Q4 '25: 60.8M Q1 '26: 30.9M Q2 '26: 3.7M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income Quarterly

-50M -25M 0 25M 50M 75M Q1 '14: -3.8M Q2 '14: -4.1M Q3 '14: -6.6M Q4 '14: -3.5M Q1 '15: -3.7M Q2 '15: -4.7M Q3 '15: -9.4M Q4 '15: -9.5M Q1 '16: -15.7M Q2 '16: -24.5M Q3 '16: -26.4M Q4 '16: -27.6M Q1 '17: -23.1M Q2 '17: -21.1M Q3 '17: -13.3M Q4 '17: -17.4M Q1 '18: -18.7M Q2 '18: -13.1M Q3 '18: -16.5M Q4 '18: 9.1M Q1 '19: -9.7M Q2 '19: -4.7M Q3 '19: -6.1M Q4 '19: -2.2M Q1 '20: 450K Q2 '20: 8.1M Q3 '20: 11.3M Q4 '20: 7M Q1 '21: 15.7M Q2 '21: 72.8M Q3 '21: 8M Q4 '21: -25M Q1 '22: -13.1M Q2 '22: -5.2M Q3 '22: 457K Q4 '22: -7.2M Q1 '23: -17.4M Q2 '23: 13M Q3 '23: 20.6M Q4 '23: 31.9M Q1 '24: 27.7M Q2 '24: 19.6M Q3 '24: 9.3M Q4 '24: 12.5M Q1 '25: 2.4M Q2 '25: 12M Q3 '25: 31.5M Q4 '25: 17M Q1 '26: 14.5M Q2 '26: -15.1M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue Quarterly

0 35M 70M 105M Q1 '17: 371K Q2 '17: 577K Q3 '17: 553K Q4 '17: 1.1M Q1 '18: 43.1M Q2 '18: 46.8M Q3 '18: 46M Q4 '18: 29.7M Q1 '19: 49.2M Q2 '19: 48.7M Q3 '19: 46.8M Q4 '19: 49.1M Q1 '20: 37.5M Q2 '20: 29.7M Q3 '20: 31M Q4 '20: 32M Q1 '21: 32.1M Q2 '21: 32.7M Q3 '21: 32.7M Q4 '21: 28.7M Q1 '22: 35.3M Q2 '22: 71.2M Q3 '22: 68.2M Q4 '22: 79.8M Q1 '23: 67.4M Q2 '23: 61.7M Q3 '23: 56.4M Q4 '23: 55.1M Q1 '24: 53.5M Q2 '24: 54.5M Q3 '24: 62.5M Q4 '24: 83.7M Q1 '25: 80.4M Q2 '25: 79.6M Q3 '25: 80.2M Q4 '25: 77.1M Q1 '26: 76.3M Q2 '26: 89.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-50M 0 50M 100M 150M Q1 '14: -3.8M Q2 '14: -2.2M Q3 '14: -4.4M Q4 '14: -7.6M Q1 '15: -1.7M Q2 '15: -4.4M Q3 '15: -6.5M Q4 '15: -8.9M Q1 '16: -11.5M Q2 '16: -20.8M Q3 '16: -19.4M Q4 '16: -23.3M Q1 '17: -23.7M Q2 '17: -17.5M Q3 '17: -12.6M Q4 '17: -13.3M Q1 '18: 29.7M Q2 '18: 55.6M Q3 '18: 41.8M Q4 '18: 42.3M Q1 '19: -8.6M Q2 '19: 14.6M Q3 '19: 6.1M Q4 '19: 15.7M Q1 '20: -6.7M Q2 '20: 43.9M Q3 '20: 34.2M Q4 '20: 22.6M Q1 '21: 20.6M Q2 '21: 29.5M Q3 '21: 17.3M Q4 '21: 36.2M Q1 '22: -25.3M Q2 '22: 40.5M Q3 '22: 42.8M Q4 '22: 66.3M Q1 '23: 27.7M Q2 '23: 99.7M Q3 '23: 74M Q4 '23: 73.3M Q1 '24: 61.9M Q2 '24: 67.4M Q3 '24: -9M Q4 '24: 84.6M Q1 '25: 55.4M Q2 '25: 72.4M Q3 '25: 78.4M Q4 '25: 123M Q1 '26: 57.1M Q2 '26: 71.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow Quarterly

-50M 0 50M 100M 150M Q3 '15: -6.7M Q4 '15: -9.1M Q3 '16: -19.5M Q4 '16: -23.6M Q1 '17: -23.7M Q2 '17: -17.9M Q3 '17: -12.9M Q4 '17: -13.5M Q1 '18: 29.3M Q2 '18: 55M Q3 '18: 39.1M Q4 '18: 40.5M Q1 '19: -11.9M Q2 '19: 13.8M Q3 '19: 4.7M Q4 '19: 14.8M Q1 '20: -7.5M Q2 '20: 43M Q3 '20: 31.8M Q4 '20: 21.1M Q1 '21: 20.1M Q2 '21: 28.8M Q3 '21: 17M Q4 '21: 35.7M Q1 '22: -25.4M Q2 '22: 40M Q3 '22: 42.7M Q4 '22: 65.4M Q1 '23: 27.5M Q2 '23: 99.7M Q3 '23: 74M Q4 '23: 73.2M Q1 '24: 61.4M Q2 '24: 67.1M Q3 '24: -9.2M Q4 '24: 84.1M Q1 '25: 54.6M Q2 '25: 72.4M Q3 '25: 78.2M Q4 '25: 122.4M Q1 '26: 56.8M Q2 '26: 70.8M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '14: 912.6K Q1 '15: 7.6M Q2 '15: 11.8M Q3 '15: 20.5M Q4 '15: 20.6M Q1 '16: 23.1M Q1 '18: 32.9M Q2 '18: 33M Q3 '18: 33M Q4 '18: 33.8M Q1 '19: 33.3M Q2 '19: 33.4M Q3 '19: 33.5M Q1 '20: 35.1M Q2 '20: 35.1M Q3 '20: 35.1M Q4 '20: 35.4M Q1 '21: 41.2M Q2 '21: 41.3M Q3 '21: 36.3M Q4 '21: 34.1M Q1 '22: 33.7M Q2 '22: 34M Q3 '22: 34.6M Q4 '22: 33.6M Q1 '23: 34.3M Q2 '23: 42.8M Q3 '23: 42.1M Q4 '23: 41.3M Q1 '24: 41.4M Q2 '24: 40.4M Q3 '24: 40.2M Q4 '24: 40.1M Q1 '25: 32.8M Q2 '25: 39.1M Q3 '25: 39.4M Q4 '25: 40.1M Q1 '26: 40.1M Q2 '26: 32.5M Q3 '15 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '14: -22.71 Q1 '15: -18.33 Q2 '15: -13.45 Q3 '15: -6.06 Q4 '15: -2.02 Q1 '16: -2.05 Q2 '16: -2.65 Q3 '16: -3.32 Q4 '16: -3.88 Q1 '17: -3.99 Q2 '17: -3.66 Q3 '17: -2.98 Q4 '17: -2.50 Q1 '18: -2.28 Q2 '18: -1.96 Q3 '18: -2.01 Q4 '18: -1.20 Q1 '19: -0.92 Q2 '19: -0.66 Q3 '19: -0.34 Q4 '19: -0.67 Q1 '20: -0.37 Q2 '20: -0.00 Q3 '20: 0.50 Q4 '20: 0.76 Q1 '21: 1.16 Q2 '21: 2.72 Q3 '21: 2.62 Q4 '21: 1.69 Q1 '22: 0.89 Q2 '22: -1.05 Q3 '22: -1.26 Q4 '22: -0.74 Q1 '23: -0.86 Q2 '23: -0.37 Q3 '23: 0.15 Q4 '23: 1.18 Q1 '24: 2.40 Q2 '24: 2.58 Q3 '24: 2.32 Q4 '24: 1.86 Q1 '25: 1.22 Q2 '25: 1.04 Q3 '25: 1.61 Q4 '25: 1.71 Q1 '26: 2.04 Q2 '26: 1.24 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.